IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâ€™s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâ€™s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-18	0.006000 $	0.00%	79,600
26-06-17	0.006000 $	-14.29%	118,330
26-06-16	0.007000 $	+1.45%	105,433
26-06-15	0.006900 $	+22.67%	155,458
26-06-12	0.005625 $	-19.64%	49,992

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 12:34:53 2026-06-18 EDT			5-day change	1st Jan Change
0.006000 ^USD	0.00%		+7.14%	-99.01%

04-05	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI
03-31	IO Biotech, Inc. Filed for Bankruptcy	CI

Market Cap	43.81M 38.2M 35.38M 33.12M 62.11M 4.13B 62.49M 420M 163M 2.03B 164M 161M 7.07B	P/E 2023	-0.95x	P/E 2024	-0.63x
Enterprise Value	-14.31M -12.47M -11.55M -10.81M -20.28M -1.35B -20.41M -137M -53.12M -664M -53.7M -52.55M -2.31B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	99.69%	Yield 2023 *	-	Yield 2024	-

04-05	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI
03-31	IO Biotech, Inc. Filed for Bankruptcy	CI
03-31	Io Biotech Inc - files voluntary chapter 7 bankruptcy petition on March 31, 2026 - SEC filing	RE
03-31	IO Biotech, Inc. Terminates Amy Sullivan as Chief Financial Officer on March 31, 2026	CI
03-31	IO Biotech, Inc. Announces Termination of Mai-Britt Zocca as Chief Executive Officer	CI
03-31	IO Biotech, Inc. Announces Management Changes on March 31, 2026	CI
02-16	CNS Pharmaceuticals, Inc. Announces Executive Appointments, Effective March 2, 2026	CI
01-30	Biotech, Inc. Announces Departure of Qasim Ahmad as Chief Medical Officer and Executive Officer, Effective February 15, 2026	CI
01-30	IO Biotech, Inc. Implements Significant Workforce Reduction as Part of Cost-Containment Measures While Exploring Strategic Alternatives	CI
01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-21	Io Biotech announces exploration of strategic alternatives	RE
01-08	Morgan Stanley Downgrades IO Biotech to Underweight, Price Target is $0.36	MT

01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-08	Morgan Stanley Downgrades IO Biotech to Underweight, Price Target is $0.36	MT
25-09-30	IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says	MT
25-09-30	TD Cowen Downgrades IO Biotech to Hold From Buy	MT

IO Biotech, Inc. Stock

Stocks

IOBTQ

US4497781090

Biotechnology & Medical Research

Valuation: IO Biotech, Inc.

Chart: IO Biotech, Inc.

Latest news : IO Biotech, Inc.

Last Transcript: IO Biotech, Inc.

Analysts' recommendations: IO Biotech, Inc.

Press Releases: IO Biotech, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: IO Biotech, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

02-02	IO Biotech Provides Corporate Update	AQ
01-30	IO Biotech Provides Corporate Update	AQ
01-21	IO Biotech Announces Exploration of Strategic Alternatives	AQ
12-15	IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications	AQ
11-26	IO Biotech Announces Participation in Upcoming December Investor Conferences	AQ

1 week	+7.14%
Current month	+76.47%
1 month	+81.82%
3 months	-96.60%
6 months	-99.10%
Current year	-99.01%

1 week	0		0.01
1 month	0		0.01
Current year	0		0.7
1 year	0		2.79
3 years	0		2.79
5 years	0		17.88
10 years	0		17.88

Manager	Title	Age	Since
Diane McDowell CTO	Chief Tech/Sci/R&D Officer	-	2021-09-30
Devin Smith CMP	Compliance Officer	58	2023-01-22
Maryann Cimino IRC	Investor Relations Contact	-	2023-03-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
25-06-04	Heidi Hunter	Free	Director	35,144	0.0533%
25-06-04	Kathleen Glaub	Free	Director	35,144	0.0533%
25-06-04	David Smith	Free	Director	35,144	0.0533%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IO BIOTECH, INC.	0.00%	+7.14%	-99.54%	-99.70%	432K
LONZA GROUP AG	+1.44%	+1.71%	-10.98%	-6.19%	43.13B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+310.97%	+534.70%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+9.34%	+41.02%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.43%	-21.94%	28B
CELLTRION, INC.	-1.90%	-1.56%	+10.24%	+21.21%	24.45B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+48.76%	+104.27%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.08%	+4.79%	12.53B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+98.13%	+80.47%	12.25B
Average	+0.37%	-0.77%	+42.27%	+73.18%	21.25B
Weighted average by Cap.	+0.77%	+1.27%	+65.47%	+110.06%

	2023	2024
Net sales	-	-
Net income	-86.08M -75.06M -69.51M -65.07M -122M -8.12B -123M -825M -320M -4B -323M -316M -13.88B	-95.49M -83.26M -77.11M -72.19M -135M -9.01B -136M -915M -355M -4.44B -358M -351M -15.4B
Net Debt	-141M -123M -114M -106M -199M -13.28B -201M -1.35B -522M -6.53B -528M -517M -22.69B	-58.12M -50.67M -46.93M -43.93M -82.39M -5.48B -82.89M -557M -216M -2.7B -218M -213M -9.37B